Innovation is crucial to fulfil the potential of industrial biotechnology for sustainable production of fuels, chemicals, materials, food and feed. Similarly, scientific and technological advances in environmental biotechnology are needed to enable novel approaches to water purification, and ‘waste-to-product’ processes thus contributing to a circular economy. Increased fundamental knowledge encompassing enzymes, microorganisms and processes are essential for progress in this field. The Department of Biotechnology covers this research area and, based on new insights, selects, designs and tests new biobased catalysts, micro-organisms, and processes.
The department encompasses five research sections:
29 August 2018
Delft biotech pioneer Mark van Loosdrecht receives Stockholm Water PrizeProfessors Mark van Loosdrecht (Delft University of Technology) and Bruce Rittmann (Arizona State University) will both receive the 2018 Stockholm Water Prize today for revolutionizing water and wastewater treatment. By developing microbiological processes in wastewater treatment, they have demonstrated the possibilities to cut costs, reduce energy consumption and even recover chemicals and nutrients for recycling.
05 July 2018
Delft Advanced Biorenewables attracts capital and commercial director for scale-up phaseSerial entrepreneur Jan Willem Klerkx participates and joins start-up Delft Advanced Biorenewables (DAB), that developed a unique technology to produce biochemicals and biofuels in a cheaper and more efficient way. Klerkx becomes shareholder and joins the management. Details about the investment are not published. DAB , a spin-off of TU Delft, has gone through an extensive development trajectory in the last four years and is now in the phase of scaling up, in which Klerkx will play an important role. Using his knowledge and experience, the serial entrepreneur regularly joins technology start-ups to strengthen them in the field of management and sales. Previously, he invested in the start-up Scyfer (artificial intelligence), which was taken over by Qualcomm last year. With DAB, Klerkx now focuses on sustainable energy. "I had the idea for a while to spend my time and energy on supporting the circular economy. What DAB does - reducing the production costs of biofuels and biochemicals - is an important contribution to this. The technology and scientific team of DAB are world-class. I look forward to making the company stronger commercially with my experience." DAB Corporate Movie from DelftAB on Vimeo . Director of DAB, Kirsten Steinbusch, is pleased with the arrival of Klerkx. "Jan Willem has proven to be able to make a difference in knowledge based start-ups. We can use his commercial skills and strategy to enable DAB to grow further." TU Delft also has an interest in DAB through ‘ Delft Enterprises ’. Director Paul Althuis: "TU Delft is committed to work on a sustainable future. That is why it is important that our scientists’ groundbreaking research also reaches the market. That is why we invest in promising technological innovations, such as those of DAB." DAB was founded in 2012 with the conviction that in the near future there will be an increasing demand for advanced fuels and chemicals that are produced from biomass. To make biobased an attractive alternative, the production process should become cost effective and scalable. DAB has developed a unique separation and reactor technology to convert organic material into biofuels and biological chemicals in a single process step, resulting in both lower costs and simplified production. DAB works closely with TU Delft and the Bioprocess Pilot Facility (BPF) to scale up the technology. The joint research project is subsidized by the Ministry of Economic Affairs, national regulations for Ministry of Economic Affairs subsidies and the ‘Top Sector Energie’ carried out by the Dutch Enterprise Agency (RVO). For more information, please contact Kirsten Steinbusch - Managing Director DAB
03 March 2016
A sustainable, good, affordable Hib vaccine for every childWith her doctoral research, TU Delft doctoral candidate Ahd Hamidi has made a major contribution to developing an innovative, scalable, affordable version of the Haemophilus influenzae (Hib) vaccine developed by Intravacc. This low-cost vaccine has now been used to protect 200 million children worldwide against Hib diseases such as meningitis, pneumonia, sepsis and otitis media. Hamidi has defended her dissertation at TU Delft on Thursday 3 March. Gram stain of Haemophilus influenzae type b bacterium Since the 1990s, children in high-income countries have been vaccinated on a large scale with Hib vaccine, which protects against Hib diseases such as meningitis. Since 1993, the Hib vaccine has also been included in the Dutch National Vaccination Programme. ‘The introduction of Hib-vaccine in developing countries was slow, mainly because of its relatively high price. Further, the local vaccine manufacturers didn’t had access to the technology needed for the production of the vaccine’, says Hamidi. In Intravacc’s Hib project she worked on process development, making a major scientific and social contribution to the availability of approved registered low-cost Hib vaccine. Her dissertation also discusses ways of optimising the process and thus reducing the cost price still further, an attractive option for both current or future partners want. Technology transfer and price reduction Hamidi’s research focused on process development and technology transfer to vaccine manufacturers in developing countries, and using mathematical models to improve process knowledge and investigate whether further process optimisation (cost reduction) is possible. In 2013, one of Intravacc’s partners marketed the Hib vaccine, as part of a combined vaccine including four others, through UNICEF at a price that was three times lower than that of existing Hib vaccines, thus bringing it within reach of large numbers of children. If a further price reduction can be achieved, the countries concerned would be able to bear the cost of the vaccine themselves in future. The knowledge gained in the Hib project has meanwhile been transferred successfully to local manufacturers in Indonesia, China (via Korea) and India. UNICEF and GAVI (the Global Alliance for Vaccines and Immunisation) are both involved in distributing the vaccine. Mathematical models Hamidi collaborated closely with experienced process designers and vaccine experts at such institutions as Intravacc (formerly the Netherlands Vaccine Institute (NVI) and the National Institute for Public Health and the Environment (RIVM)) and with various vaccine manufacturers in Indonesia, China, Korea and India. She used the Delft process design method and the knowledge of experts at TU Delft to develop the mathematical models. This enabled predictable models of the Hib process developed and performing sensitivity analyses on the Hib process, thus showing the impact of particular choices on cost. ‘This approach can help both current and future Hib partners to make choices, for example between the use of existing production facilities and building new ones, or the optimum scale of production,’ explains Hamidi. Other vaccines This rational Delft method of process design, says Hamidi, can also be used very efficiently to develop other vaccines. While the process was being developed it was decided to protect it with a patent: partners have a license and their production method protected. More information After graduating in Chemical Engineering (MSc) and Bioprocess Design (PDEng) at TU Delft, Hamidi started working for the forerunners of Intravacc as a process technologist and subsequently project manager and technology transfer expert. In her dissertation she shares the lessons learned from the Hib project so that similar technology transfer projects can benefit from the experience. The project will help to reduce child mortality, one of the UN Millennium Development Goals. Hamidi published in the renowned journal Biotechnology Process in January 2016: ‘ Process development of a new Haemophilus influenzae type b conjugate vaccine and the use of mathematical modeling to identify process optimization possibilities ’ Contact For more information about the dissertation 'Towards a sustainable, quality and affordable Haemophilus influenzae type b vaccine for every child in the world' , please contact A. Hamidi MSc, A.Hamidi@tudelft.nl / Ahd.Hamidi@intravacc.nl tel. +31 30 2742066 or Claire Hallewas (TU Delft Press Officer), firstname.lastname@example.org , +31 6 4095 3085.
03 February 2016
Interview by BNR radio with Peter Mooij about the fattest algeaTo produce biodiesel using algae, you can revert the best in Darwin's theory. For scientists, however clever on genetic engineering, nature still outwits us from Delft research Peter Mooij, TU Delft on BNR radio (in Dutch): "You need to reward an algea for the trick he does"
15 January 2016